Quoin Pharmaceuticals Ltd.
QNRX · XNASCIK 1671502fmd_10PJ3P3EMV8Z3TKM5PG1EQA3PRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 33 periods
| Line item | FY2017 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | – | – | – | – |
| Research and development | 3 | 0 | 0 | 2 | 3 | 3 | 4 | 10 |
| Selling, general and administrative | 1 | 2 | 1 | 4 | 7 | 6 | 6 | 6 |
| Operating income | (7) | (6) | (4) | – | – | – | – | – |
| Interest expense | 1 | 0 | 0 | 1 | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | 1 | 0 |
| Other non-operating income (expense) | – | – | (0) | (15) | (0) | 1 | 1 | 0 |
| Income before taxes | – | – | – | – | – | – | (9) | (16) |
| Net income | (8) | (2) | (2) | (21) | (9) | (9) | (9) | (16) |
| Net income to common shareholders | – | – | – | (21) | (9) | (9) | – | – |